Recommendation and upside
We initiate coverage of Crossject, a new entrant in the New Therapeutic Entities field. Its differentiating feature is its delivery mechanism, Zeneo, a pretty unique injection system. Crossject has completed clinical trials on a first well-known molecule, Methotrexate, with another six to go in the pipeline. The current market capitalisation stands at c. €50m based on a share price of €7.5, while we see a massive potential upside (over 220%), with a target price of €24 ....
25 Feb 2016
Initiating coverage of Crossject.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Initiating coverage of Crossject.
Crossject SA (ALCJ:PAR) | 0 0 (-3.4%) | Mkt Cap: 38.7m
- Published:
25 Feb 2016 -
Author:
Fabrice Farigoule -
Pages:
31
Recommendation and upside
We initiate coverage of Crossject, a new entrant in the New Therapeutic Entities field. Its differentiating feature is its delivery mechanism, Zeneo, a pretty unique injection system. Crossject has completed clinical trials on a first well-known molecule, Methotrexate, with another six to go in the pipeline. The current market capitalisation stands at c. €50m based on a share price of €7.5, while we see a massive potential upside (over 220%), with a target price of €24 ....